#Canada #Mississauga #Kye Pharmaceuticals #ADHD treatment #DYANAVEL XR

Kye Pharmaceuticals Launches Dyanavel® XR Tablets in Canada

Kye Pharmaceuticals Inc., a prominent Canadian pharmaceutical firm, is delighted to announce the nationwide availability of Dyanavel® XR (amphetamine extended-release) tablets aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This new medication is now accessible through pharmacies and wholesalers across Canada, reinforcing Kye's commitment to providing targeted, innovative healthcare solutions.

Dyanavel® XR has received authorization for use in adults aged 18 and older and for children between the ages of 6 and 12. As a long-acting psychostimulant, it is recognized in the clinical practice guidelines by the Canadian ADHD Resource Alliance (CADDRA) as a first-line treatment. This classification underscores the importance of establishing effective methodologies in ADHD management, necessitating a variety of treatment options tailored to diverse patient needs.

ADHD is a chronic neurodevelopmental disorder that can substantially affect learning, behavior, and day-to-day functioning. Reportedly, about 3–5% of adults and 5–9% of children and adolescents in Canada are diagnosed with this condition. Those with ADHD often encounter persistent challenges with attention regulation, focus, and executive functioning. As healthcare professionals advocate for a broader range of treatment alternatives that can accommodate these varied needs, the introduction of Dyanavel® XR comes as a timely advancement.

Dr. Jane Liddle, a well-respected pediatrician and CADDRA Chairperson, articulated her enthusiasm for the new treatment option.